Want to join the conversation?
Biopharmaceutical company $MDCO said it has begun enrolling patients in the ORION-1 Phase 2 study to compare the effect of different doses of ALN-PCSsc given as subcutaneous injections in a quarterly or bi-annual dosing regimen in subjects with atherosclerotic cardiovascular disease (ASCVD) or risk equivalent ASCVD and elevated LDL-C.
$BIG looks promising to me. Feels like it’s a good time to put some money on it.
$TWTR rolled out an iOS update Dec. 8 night that killed its famous "@" symbol. This lead to confusion among the iOS users when they tried it to reply to tweets.